Homeopathy re-revisited: Is homeopathy compatible with biomedical observations?

Archives of Internal Medicine

Volumn 159, Issue 17, 1999, Pages 1981-1987

  Eskinazi, Daniel ^a  

^a Columbia Univ Coll Phys Surgs ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ALLOPURINOL; ANESTHETIC AGENT; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIESTROGEN; ANTINEOPLASTIC AGENT; ATROPINE; AUTACOID; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; HEAVY METAL; INTERFERON; INTERLEUKIN 2; METENKEPHALIN; MONOAMINE OXIDASE INHIBITOR; OPIATE; SALICYLIC ACID DERIVATIVE; SCOPOLAMINE; SEROTONIN; SOMATOSTATIN; SUBSTANCE P; THIAZIDE DIURETIC AGENT; TRANSFORMING GROWTH FACTOR BETA; TRICYCLIC ANTIDEPRESSANT AGENT; TUMOR NECROSIS FACTOR; VASOACTIVE INTESTINAL POLYPEPTIDE;

ACUPUNCTURE; ALTERNATIVE MEDICINE; ARTICLE; BIOCHEMISTRY; BIOMEDICINE; CONSUMER; DILUTION; HOMEOPATHY; HUMAN; MANIPULATIVE MEDICINE; MEDICAL PRACTICE; MEDICAL PROFESSION; MEDICAL RESEARCH; MEDICINAL PLANT; NONHUMAN; PRIORITY JOURNAL;

EVIDENCE-BASED MEDICINE; HOMEOPATHY; HUMANS;

EID: 0033610253     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.159.17.1981     Document Type: Article

References (52)

1. Eisenberg DM, Kessler RC, Foster C, Norlock FE, Calkins DR, Delbanco TL. Unconventional medicine in the United States: prevalence, cost and pattern of use. N Engl J Med. 1993;328: 246-252.
2. Fisher P, Ward A. Complementary medicine in Europe. BMJ. 1994;309:107-111.
3. Boissel JP, Ernst E, Fisher P, Fulgraff G, Garattini S, de Lange de Klerk E. Overview of data from homeopathic medicine trials: report on the efficacy of homeopathic intervention over no treatment or placebo. In: Report of Homeopathic Medicine Research Group. Brussels, Belgium: European Commission; 1996.
4. Nau JY. Le Conseil de l'ordre des médecins réclame une reconnaissance officielle de l'homéopathie. Le Monde. February 13, 1998: 10.
5. Integrated Health Care: A Way Forward for the Next Five Years. Foundation for Integrated Medicine (on behalf of the steering committee for the Prince of Wales's Initiative on Integrated Medicine, London, England); 1997.
6. Ernst E, Kaptchuk TJ. Homeopathy revisited. Arch Intern Med. 1996;156:2162-2163.
7. Hahnemann S. Organon of Medicine. 6th ed. Blaine, Wash: Cooper Publishing; 1982.
8. Bellavite P, Signorini A. Homeopathy: A Frontier in Medical Science. Berkeley, Calif: North Atlantic Books; 1995.
9. Goodman LS, Gilman A. The Pharmacological Basis of Therapeutics, Ninth Edition. New York, NY: McGraw-Hill; 1996.
10. Luckey TD. Radiation hormesis in cancer mortality. Chin Med J. 1994;107:627-630.
11. Eskinazi DP, Molinaro GA. Non-stimulatory concentrations of concanavalin A can modulate subsequent stimulation by the same mitogen. In: Ultra Low Doses. Washington, DC: Taylor & Francis; 1991:119-126.
12. van Wijk R, Ooms H, Wiegant FAC, et al. A molecular basis for understanding the benefits from subharmful doses of toxicants: an experimental approach to the concept of hormesis and the homeopathic similia law. Biomed Ther. 1997;15: 4-13.
13. Pollycove M. Nonlinearity of radiation health effects. Environ Health Perspect. 1998;106(suppl): 363-368.
14. Calabrese EJ, Baldwin LA. Hormesis as a biological hypothesis. Environ Health Perspect. 1998; 106(suppl):357-362.
15. Siskind GW. Immunological tolerance In: Paul W, ed. Fundamental Immunology. New York, NY: Raven Press; 1984:537-558.
16. Townsend JF, Luckey TD. Hormoligosis in pharmacology. JAMA. 1960;173:44-48.
17. Neafsey PJ. Longevity hormesis: a review. Mech Ageing Dev. 1990;51:1-31.
18. Furst A. Hormetic effects in pharmacology: pharmacological inversions as prototypes for hormesis. Health Phys. 1987;52:527-530.
19. Masero EJ. Hormesis and the antiaging action of dietary restriction. Exp Gerontol. 1997;33:61-66.
20. Calabrese EJ, Baldwin LA. Possible examples of chemical hormesis in a previously published study. J Appl Toxicol. 1993;13:169-172.
21. Doutremepuich C, Pailley D, Anne MC Seize O, Paccalin J, Quilichini R. Template bleeding time after ingestion of ultra-low doses of acetylsalicylic acid in healthy subjects. Thromb Res. 1987; 48:501-504.
22. Aguejouf O, Belougne-Malfati E, Doutremepuich F, Belon P, Doutremepuich C. Thromboembolic complications several days after a single-dose administration of aspirin. Thromb Res. 1998;89: 123-127.
23. Luckey TD. Antibiotics in nutrition. In: Goldberg H, ed. Antibiotics: Their Chemistry and Non-Medical Uses. New York, NY: D van Nostrand Co Inc; 1959:174-321.
24. Berkoff R, ed. The Merck Manual. 14th ed. Rahway, NJ: Merck Sharp & Dohme Research Laboratories, Division of Merck & Co; 1982:279, 314.
25. Okumura MN, Ichimaru M, Nakamura T, Kondo S. Apparently beneficial effects of low to intermediate A-bomb radiation on human lifespan. Int J Radiat biol. 1990;58:1035-1043.
26. Cragg B, Rees S. Increased body:brain ratio on developing rats after low exposure to organic lead. Exp Neurol. 1984;86:113-121.
27. Weis P, Weis JS. Cadmium acclimation and hormesis in Fundus heteroclitus during fin regeneration. Environ Res. 1986;39:356-363.
28. Kimata H, Yoshida A, Fujimoto M, Mikawa H. Effect of vasoactive intestinal peptide, and substance P on spontaneous IgE and lgG4 production in atopic patients. J Immunol. 1993;150: 4630-4640.
29. Bonavida B, Tsuchitani T, Zighelboim J, Berek J. Synergy is documented in vitro with low-dose recombinant tumor necrosis factor, cisplatin, and doxorubicin in ovarian cancer cells. Gynecol Oncol. 1990;28:333-339.
30. Nio DA, Moylan RN, Roche JK. Modulation of t lymphocyte function by neuropeptides. J Immunol. 1993;150:5281-5288.
31. Rameshwar P, Gascon P, Ganea D. Stimulation of IL-2 production in murine lymphocytes by substance P and related tachykinins. J Immunol. 1993; 151:2484-2496.
32. Parekh T, Saxena B. Reibman J, Cronstein BN, Gold LI. Neutrophil chemotaxis I response to TGF-β isofornts (TGF-β1, TGF-β2, TGF-β3) is mediated by fibronectin. J Immunol. 1994;152:2456-2466.
33. 2+ modulation in buman B cell lines. J Immunol. 1992;149:4074-4081.
34. DeRose V, Robbins RA, Snider RM, et al. Substance P increases neutrophil adhesion to bronchial epithelial cells. J Immunol. 1994;152:1339-1346.
35. Rola-Pleszczynski M, Stankova J. Differentiation-dependent modulation of TNF production by PAF in human HL-60 myeloid leukemia cells. J Leukoc Biol 1992;51:609-616.
36. Junier MP, Tiberghien C, Rougeot C, Fafeur V, Dray F. Inhibitory effect of platelet-activating factor (PAF) on luteinizmg hormone-releasing hormone and somatostatin release from rat median eminence in vitro correlated with the characterization of specific PAF receptor sites in rat hypothalamus. Endocrinology 1988;123:72-80.
37. Williamson SA, Knight RA, Lightman SL, Hobbs JR. Differential effects of β-endorphin fragments on human natural killing. Brain Behav Immun. 1987;1:329-335.
38. Brenneman DE, Gozes I. A femtomolar-acting neuroprotective peptide. J Clin Invest. 1996;97:2299-2307.
39. Adams DH, Hathaway M, Shaw J, Burnet D, Elias E, Strain AJ. Transforming growth factor-β induces human t lymphocyte migration in vitro. J Immunol. 1991;147:609-612.
40. 4 stimulate the release of luteinizmg hormone-releasing hormone from rat median eminence in vitro. Brain Res. 1987;416:54-58.
41. Orencole SF, Dinarello C. characterization of a subclone of the D10.G4.1 helper T-cell line which proliferates to attomolar concentrations of interteukin-1 in trie absence of mitogens. Cytokine. 1989; 1:14-22.
42. Watson MW, Hessinger DA. Antagonistic frequency tuning of hair bundles by different chemoreceptors regulates nematocyst discharge. J Exp Biol. 1994;187:57-73.
43. van der Meer JW, Barza M, Wolff SM, Dinarello CA. A low dose of recombinant interleukin 1 protects granulocytopenic mice from lethal gram-negative infections. Proc Natl Acad Sci U S A. 1988; 85:1620-1623.
44. Flood JF, Morley JE, Roberts E. Pregnenolone sulfate enhances post-training memory processes when injected in very low doses into limbic system structures: the amygdala is by far the most sensitive. Proc Natl Acad Sci U S A. 1995;92: 10806-10810.
45. Kaisling KE. Peripheral mechanisms of pheromone reception in moths. Chem Senses. 1996; 21:257-268.
46. Linde K, Clausius N, Ramirez G, et al. Are the clinical effects of homeopathy placebo effects? a meta-analysis of placebo-controlled trials. Lancet. 1997; 350:834-843.
47. Sainte Laudie J, Sambucy JL, Belon P. Biological activity of ultra low doses, I: effect of ultra low doses of hislamine on human basophil degranulation triggered by D. Pteronyssinus extract. In: Ultra Low Doses. Washington, DC: Taylor & Francis; 1991:127-138.
48. Schiff M. The Memory of Water. London, England: Harper Collins; 1955.
49. Thomas Y, Schiff M, Belkadi L, Jurgens P, Kahhak L, Benveniste J. Activation of human neutrophils by electronically transmitted phorbol myristate acetate. Med Hypotheses. In press.
50. Benveniste J. Letter to the editor. Lancet. 1998; 351:367.
51. Eskinazi D. Some questions and thoughts on research in homeopathy. Br Homeopath J. 1998; 87:33-38.
52. Vandenbrook JP. Homeopathy trials: going nowhere. Lancet. 1997;350:824.